I like how this stock has been trading recently. Waiting continues for the big day to come. The phase 3 product Mino-Lok is well on its way of getting approved imo. Only a matter of a few weeks/months. Current Market Cap of around $65 Million is way too low... Mino-Lok Market (Worldwide)> $1.5B "With modest penetration at conservative pricing, we believe that >$500M peak year U.S. sales is achievable."
this is not consultation or advice. tuch price 1.1 and stop there. I Thinkthat CXTR will go up. the orange line is Dynamic support line. the target is the green line 1.23. if the price break the support line , I think CXTR go to 1.03.
this is not consultation or advice. CXTR: the price met the low target indicator(red line). as long as the price will stay under the EMA (orange line), and the dots on the halfway indicator (blue line) will stay red, CXTR will stay bearish.
this is not consultation or advice. All Indicator lines used as dynamic support and resistance, that change reliance on the price and time. When the price reach and meet one of the indicator, the trend stop, and new trend begin. the system show the next price target at high probability(no 100%). CXTR: the price met the lower target indicator(red line), and didn't go below it. as long as the price below EMA (orange line), the trend is bearish. if the price go above the EMA, the first target will be the Halfway indicator(blue line).
Below are some interesting quotes from yesterdays Webcast. Mino-Lok, we should know if we meet superior efficacy to terminate the trial by beginning of 2021 (January). We are at over 60% events for MinoLok and the DNC told us they think they have good news for us at 69 events. We are attempting to get non dilutive financing for NoveCite. We think the share price will be much higher soon. Citius Pharmaceuticals to Present at H.C. Wainwright 6th Annual Israel Conference 12 November 2020 https://journey.ct.events/view/43d1a83f-22aa-464f-a250-de8240b51195
this is not consultation or advice. All Indicator lines used as dynamic support and resistance, that change reliance on the price and time. When the price reach and meet one of the indicator, the trend stop, and new trend begin. the system show the next price target at high probability(no 100%). CXTR: the price met the low target indicator(red line) and break it down. as long as the price will stay under the EMA (orange line), CXTR will stay bearish.
this is not consultation or advice. All Indicator lines used as dynamic support and resistance, that change reliance on the price and time. When the price reach and meet one of the indicator, the trend stop, and new trend begin. the system show the next price target at high probability(no 100%). CXTR: the price met the low target indicator(red line) and break it down. As long as the price will stay under the EMA (orange line), CXTR will stay bearish.
Upcoming milestones in Q1 2021 will hopefully propel the share price much higher... Citius Announces Results of Study that Mino-Lok Eradicates S. aureus Biofilm More Effectively and Expeditiously than Components November 30, 2020 -- Mino-Lok superior to EDTA and Ethanol in eradicating most worrisome pathogen -- Two strains of resistant Staphylococcus aureus tested -- Study reinforces previous studies that all three components needed for some biofilm forming pathogens https://ir.citiuspharma.com/press-r...ces-results-of-study-that-mino-lok-eradicates
this is not consultation or advice. All Indicator lines used as dynamic support and resistance, that change reliance on the price and time. When the price reach and meet one of the indicator, the trend stop, and new trend begin. the system show the next price target at high probability(no 100%). CXTR: the price break up the EMA and the Halfway indicator. The target is the High target indicator. As long as the price above the EMA the trend is bullish.
Citius Pharmaceuticals Subsidiary NoveCite Announces Data from a Study of Induced Mesenchymal Stem Cell ("i-MSC") Therapy in an in vivo Model of Acute Respiratory Distress Syndrome ("ARDS") December 08, 2020 --Interim results indicate i-MSC therapy improves oxygenation and reduces lung injury --Efficiently manufactured higher potency mesenchymal stem cells offer promising therapeutic approach https://ir.citiuspharma.com/press-r...aceuticals-subsidiary-novecite-announces-data
A very interesting interview, in particular the information on the phase 3 product Mino-lok (16:55 minutes): „… it is coming very close to the end, where we stop the studies…” https://ehealthradio.podbean.com/e/...d-commercialization-of-critical-care-products
Today's news release will hopefully contribute to stop the trial of the phase 3 Mino-Lok product sooner than anticpated. I am hoping for January 2021... Citius Holds Webinar Series on Conducting Mino-Lok Phase 3 Trial During COVID-19 December 15, 2020 https://ir.citiuspharma.com/press-r...webinar-series-on-conducting-mino-lok-phase-3 Participating in the webinar were 18 clinical trial sites and 30 investigators or site staff from the following institutions: Anne Arundel Medical Center Ascension Via Christi Hospital Carolinas Medical Center Edward Hines Jr VA Hospital Indiana Blood and Marrow Transplant Lutheran Hospital in Illinois Manati Medical Center Ponce Research Institute Salem VA Medical Center University Hospitals Cleveland Medical Center University of Florida University of Kentucky University of Massachusetts Memorial Medical Center University of New Mexico VA Caribbean Healthcare System VA Sierra Nevada Health Care System "We initially held one webinar, but after receiving very positive feedback, we have decided to expand into a series of webinars," Holubiak continued. "This once again affirms there is definitely an unmet need and with that a great deal of interest in salvaging infected central lines."
Citius Pharmaceuticals to Present Update on Proprietary Product Candidates at Two Virtual Conferences in January January 06, 2021 https://ir.citiuspharma.com/press-r...rmaceuticals-to-present-update-on-proprietary "We have exciting developments to discuss at our January conferences and look forward to greeting investors virtually," said Mr. Myron Holubiak. "From our NoveCite subsidiary, interim data from a proof-of-concept large animal study of induced mesenchymal stem cell ("i-MSC") therapy in an in vivo model of Acute Respiratory Distress Syndrome ("ARDS") shows improvement in critical parameters, such as improved oxygenation, less systemic shock, and reduced lung injury, compared to the control group. For Mino-Lok we recently conducted a series of webinars to provide Phase 3 trial updates and discuss the role Mino-Lok may play in the treatment of Central Line Associated Blood Stream Infections ("CLABSIs"). In spite of the headwinds from the Covid-19 pandemic, we have been able to continue to recruit patients for our pivotal trial. Mino-Lok is nearing completion of its phase 3. Mino-Wrap's novel approach to reducing post-mastectomy infections associated with the use of a tissue expander is on track in its preclinical stage, and, finally, we expect to file an IND for Halo-Lido in the near term and initiate a Phase 2b trial later this year."
10-K Fiscal Year Ended Sep 30, 2020 https://ir.citiuspharma.com/all-sec-filings/content/00012139… "The 75% interim analysis is expected to be completed by March 2021." https://clinicaltrials.gov/ct2/show/NCT02901717 "Estimated Study Completion Date : February 2021" Citius Pharmaceuticals to Present at H.C. Wainwright 6th Annual Israel Conference 12 November 2020 CEO Myron Holubiak: "Mino-Lok, we should know if we meet superior efficacy to terminate the trial by beginning of 2021 (January). We are at over 60% events for MinoLok and the DNC told us they think they have good news for us at 69 events." (see one of my previous posts)
Rebroadcast Link (free registration necessary) Noble Capital Markets Seventeenth Annual Small & Microcap Investor Conference 19 January 2021 https://t.co/DrDMnd5zyd?amp=1 Executive Chairman Leonard Mazur: „We are almost through with the clinical trial itself” Trial continuation in Covid-19 times was a challenge as most hospitals stopped trial programs. “What is remarkable about it though we still have a small handful of hospitals which are recruiting patients. We get a small number monthly but it is adding up” “We believe somewhere towards the end of the first quarter or towards the beginning of the second quarter we are going to get a readout drug monitoring committee on data readout of the mino-lok trial. That is a very critical read-out for us.”
Let's see if something new will be reported tomorrow... Citius Pharmaceuticals to Present Update on Mino-Lok and Other Therapies at the Virtual Investor Conferences Small and Microcap Showcase on February 4 February 02, 2021 https://ir.citiuspharma.com/press-r...maceuticals-to-present-update-on-mino-lok-and
The date of this prospectus is February 5, 2021 https://newsfilter.io/a/aa0192513f42cb55ef93ed2b8ef63f89 In September 2020, we announced that another DMC meeting was held to review the data being generated and analyzed in the Mino-Lok Phase 3 trial based on progress to date, and to make recommendations to us as to any action that may be necessary regarding the study. After reviewing these data, the DMC members stated that they did not find any safety signals; and they also recommended continuing the trial without any modifications. The DMC further conducted an ad hoc meeting and agreed with the Company that a 75% interim analysis be conducted as planned in which superior efficacy is evaluated. Due to the COVID-19 pandemic, the interim analysis will be performed at the 65% threshold and is expected to be completed by March 2021 with the DMC convening in April 2021.
Dawson James reiterated their buy rating and adjusted PT to $6 to reflect dilution from recent offering. "We applaud the move as the company now should have enough capital to commercialize Mino-Lok. Our model assumes dilution, so this raise has only a slight impact on our valuation with our price target adjusting from $7.00to $6.00 due to rounding" January 26, 2021 https://dawsonjames.com/wp-content/uploads/2021/01/CTXR.1.26.21.pdf
Citius Pharmaceuticals Issues Shareholder Letter with Corporate Update on Recent Achievements and Anticipated Milestones for 2021 February 16, 2021 -2021 Expected to be a Banner Year for Advancing Three Product Platforms in the Clinic: -Mino-Lok® Interim Efficacy Analysis -Halo-Lido filing IND and in Phase 2b trial -Mino-Wrap™ in Pre-Clinical Development, targeting IND by end of year -NoveCite subsidiary progressing with: continued data collection from an ongoing proof-of-concept sheep ARDS model; initiating the manufacture of clinical-grade induced-mesenchymal stem cells (i-MSCs); and implementation of FDA-required animal GLP toxicology studies https://ir.citiuspharma.com/press-r...harmaceuticals-issues-shareholder-letter-with
